RCM
GILD icon

RB Capital Management’s Gilead Sciences GILD Stock Holding History

RB Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,740
Closed -$212K – 113
2018
Q3 		$212K Sell
2,740
-187
-6% -$14.1K 0.19% 110
2018
Q2 		$207K Sell
2,927
-71
-2% -$5.01K 0.15% 126
2018
Q1 		$226K Buy
2,998
+21
+0.7% +$1.67K 0.18% 115
2017
Q4 		$213K Sell
2,977
-112
-4% -$8.51K 0.15% 122
2017
Q3 		$250 Buy
3,089
+43
+1% +$3.29K ﹤0.01% 101
2017
Q2 		$216K Sell
3,046
-56
-2% -$3.73K 0.19% 107
2017
Q1 		$211K Sell
3,102
-10
-0.3% -$703 0.2% 99
2016
Q4 		$223K Buy
+3,112
New +$231K 0.22% 97

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RB Capital Management's GILD Position: Q4 2018 in Review

RB Capital Management sold out of Gilead Sciences (GILD) in Q4 2018, closing a stake of 2,740 shares — an estimated $212K sold.

RB Capital Management first reported a position in GILD in Q4 2016 and held it in 8 quarters. The position peaked at $226K in Q1 2018. 1,496 funds tracked by Wall St. Rank hold GILD as of Q4 2018.

  • RB Capital Management reported no remaining Gilead Sciences position as of Q4 2018 after selling out during the quarter.
  • RB Capital Management sold 2,740 Gilead Sciences shares in Q4 2018, an estimated $212K.
  • RB Capital Management first reported a position in Gilead Sciences in Q4 2016 and held it in 8 quarters.
  • RB Capital Management's Gilead Sciences position peaked at $226K in Q1 2018.
  • 1,496 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2018.

Based on RB Capital Management's 13F filing for Q4 2018, filed 15 Jan 2019.